BioNanoSim Overview
BioNanoSim (BNS) has developed a proprietary technology platform for the nano-encapsulation of drugs to improve delivery profile and therapeutic performance. Research conducted by Professor Simon Benita and his team has demonstrated the potential of BNS's nano-encapsulation technology to design innovative routes of administration across a range of therapeutic areas including oncology, ophthalmology, and metabolic diseases. In addition, BNS is using its nano-encapsulation technologies to develop topical and ocular cannabis-based products.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology
Immune Pharmaceuticals has entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd for a novel topical nano-capsule formulation of cyclosporine. The formulation, developed by Professor Simon Benita, can be absorbed through the skin and has shown therapeutic levels of cyclosporine in preclinical models. Immune intends to accelerate the development of this product candidate for the treatment of chronic inflammatory skin disorders. Under the agreement, Immune will fund further development and BioNanoSim will be eligible for certain milestones and royalties on sales.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6M |
| Last funding | $6M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 0 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.bionanosim.com/ |
Locations
Hadassah Ein Kerem, Jerusalem, Israel
Photos & Videos
1 item(s)
